v3.26.1
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Zynext Ventures USA LLC
MiNK Therapeutics, Inc.
Common Stock [Member]
Common Stock [Member]
Zynext Ventures USA LLC
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Zynext Ventures USA LLC
Treasury Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Non-controlling Interest [Member]
Accumulated Deficit [Member]
Series A-1 convertible preferred stock [Member]
Preferred Stock [Member]
Beginning balance at Dec. 31, 2024 $ (306,424)     $ 236   $ 1,857,662     $ (1,398) $ 19,956 $ (2,182,880) $ 0
Balance, shares at Dec. 31, 2024       23,635               32
Net income (loss) (26,370)                 (1,104) (25,266)  
Other comprehensive income (loss) (70)               (70)      
Share-based compensation 3,184         2,587       597    
Shares sold at the market 6,343     $ 28   6,315            
Shares sold at the market, shares       2,783                
Issuance of warrants 398         398            
Payment of CEO payroll in shares 89     $ 1   88            
Payment of CEO payroll In shares, shares       33                
Issuance of shares for services 39         39            
Issuance of shares for services, shares       11                
Issuance of shares in connection with debt agreement 220     $ 1   219            
Issuance of shares in connection with debt agreement, shares       66                
Vesting of nonvested shares, shares       1                
Exercise of stock options and employee share purchases 44         43       1    
Exercise of stock options and employee share purchases, shares       18                
Issuance of shares for employee salaries 149         171   $ (22)        
Issuance of shares for employee salaries, shares       24       (8)        
Retirement of treasury shares related to employee withholding           (22)   $ 22        
Retirement of treasury shares related to employee withholding, share       (8)       8        
Ending balance at Mar. 31, 2025 (322,398)     $ 266   1,867,500     (1,468) 19,450 (2,208,146) $ 0
Balance, shares at Mar. 31, 2025       26,563               32
Beginning balance at Dec. 31, 2024 (306,424)     $ 236   1,857,662     (1,398) 19,956 (2,182,880) $ 0
Balance, shares at Dec. 31, 2024       23,635               32
Share-based compensation                   1,506    
Ending balance at Dec. 31, 2025 (277,861)     $ 353   1,911,740     (439) (6,750) (2,182,765)  
Balance, shares at Dec. 31, 2025       35,320               32
Net income (loss) 39,206   $ (1,206)             (20) 39,226  
Other comprehensive income (loss) 2               2      
Share-based compensation 774         766       8    
Shares sold at the market 996 $ 6,423   $ 3 $ 21 993 $ 6,402          
Shares sold at the market, shares       284 2,133              
Payment of CEO payroll in shares 88         88            
Payment of CEO payroll In shares, shares       27                
Modification of warrants 435         435            
Issuance of shares for services 1,394     $ 4   1,390            
Issuance of shares for services, shares       418                
Issuance of shares in connection with debt agreement 441     $ 2   439            
Issuance of shares in connection with debt agreement, shares       141                
Vesting of nonvested shares       $ 2   (2)            
Vesting of nonvested shares, shares       158                
Employee share purchases 55         55            
Employee share purchases, shares       21                
Issuance of shares for employee salaries 64         91   $ (27)        
Issuance of shares for employee salaries, shares       28       (8)        
Retirement of treasury shares related to employee withholding           (27)   $ 27        
Retirement of treasury shares related to employee withholding, share       (8)       8        
Ending balance at Mar. 31, 2026 $ (227,983)     $ 385   $ 1,922,370     $ (437) $ (6,762) $ (2,143,539)  
Balance, shares at Mar. 31, 2026       38,522               32